A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER II
Latest Information Update: 12 Apr 2021
At a glance
- Drugs Adalimumab (Primary)
- Indications Hidradenitis suppurativa
- Focus Registrational; Therapeutic Use
- Acronyms PIONEER II
- Sponsors Abbott Laboratories; AbbVie
- 02 Apr 2021 Results assessing Baseline and week 12 plasma samples from the PIONEER studies were used to assess the levels of circulating proteins by multiplex assays and enzyme linked immunosorbent assays published in the British Journal of Dermatology
- 24 Dec 2019 Results of post hoc analysis of PIONEER 1 and 2 individual patient data evaluating the efficacy of adalimumab versus placebo using the International Hidradenitis Suppurativa Severity Score System (IHS4) published in the Journal of the American Academy of Dermatology
- 27 Mar 2019 Results evaluating the optimal medium-term adalimumab maintenance dosing strategy in moderate-to-severe HS using PIONEER I and PIONEER II trials published in the British Journal of Dermatology